A controlled study on the effect of pentoxifylline and an ergot alkaloid derivative on regional cerebral blood flow in patients with chronic cerebrovascular disease.
Regional cerebral blood flow (rCBF) in 90 patients with CBF decreased due to vascular diseases was studied by using the xenon 133 inhalation technique and a 32-detector setup. Whereas 30 patients received their standard basic therapy only and were regarded as controls, 30 others received 3 x 2 mg/day of an ergot alkaloid (co-dergocrine mesylate), and 30 others received 3 x 400 mg pentoxifylline (slow-release formulation)/day orally. Therapy was performed for eight weeks and CBF measured before start of treatment, after a four-week treatment period, and at the end of the study. CBF did not change significantly in the control group; both the pentoxifylline and the ergot alkaloid group presented with a significant increase in the CBF. This positive effect was significantly more pronounced in the pentoxifylline group and affected more ischemic than other brain tissues. In addition, symptoms like sleep disturbances, vertigo, and tinnitus improved significantly during the pentoxifylline observation period.
Hartmann
A
A
Neurologische Universitätsklinik Bonn, West Germany.
Tsuda
Y
Y
D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004876:Ergot Alkaloids / Q000627:therapeutic use*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010431:Pentoxifylline / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D011897:Random Allocation; D012647:Self-Assessment; D013805:Theobromine / Q000031:analogs & derivatives*; D013997:Time Factors; D014980:Xenon Radioisotopes
D004876:Ergot Alkaloids; D014980:Xenon Radioisotopes; D013805:Theobromine; D010431:Pentoxifylline